Evidence mapPaperPMID 39350406Full record

ReviewCombinatorial chemistry & high throughput screening2025

Structural Insights and Biological Activities of Furan-Based Drugs in the Treatment of Human Diseases.

Avinash Kumar Mishra, Kuldeep Singh, Sunam Saha, Harsh Bharadwaj, Jeetendra Kumar Gupta, Kamal Shah, Shivendra Kumar, Divya Jain, Hritik Verma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Avinash Kumar MishraDepartment of Pharmaceutical Chemistry, Rajiv Academy for Pharmacy, Mathura, U.P. India.
Kuldeep SinghDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, India.ORCID 0000-0001-8772-8157
Sunam SahaDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Research, GLA University, Mathura, India.ORCID 0000-0003-1911-940X
Harsh BharadwajDepartment of Pharmaceutical Chemistry, Anand College of Pharmacy, Keetham, Agra, India.
Jeetendra Kumar GuptaDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, India.
Kamal ShahDepartment of Pharmaceutical Chemistry, Institute of Pharmaceutical Research, GLA University, Mathura, India.
Shivendra KumarDepartment of Pharmacology, Rajiv Academy for Pharmacy, Mathura, U.P. India.ORCID 0000-0002-2287-6981
Divya JainDepartment of Microbiology, School of Applied and life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
Hritik VermaDepartment of Pharmaceutical Chemistry, Rajiv Academy for Pharmacy, Mathura, U.P. India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases present significant public health challenges, driving the search for innovative therapeutic strategies. This review explores the neuroprotective potential of furan-containing compounds, which are derived from various natural and synthetic sources. These compounds are observed for their diverse pharmacological activities, including antioxidant and anti-inflammatory properties. By scavenging free radicals and mitigating oxidative stress, they address a key aspect of neurodegeneration. Additionally, furan derivatives modulate inflammatory pathways, potentially reducing neuroinflammation, a critical factor in the progression of these disorders. The review also highlights the impact of these compounds on neuronal survival and regeneration, suggesting their role in promoting neurogenesis and enhancing neuronal plasticity. Their interactions with neurotransmitter systems further support their neuroprotective effects, particularly in maintaining synaptic function and neurotransmission. The potential applications of furan-containing compounds are discussed concerning specific neurodegenerative diseases, such as Alzheimer's and Parkinson's. Insights from preclinical studies and in vitro experiments underscore their therapeutic promise across various experimental models. While still in the early stages of research, the evidence suggests that furan-containing compounds could be valuable in developing effective interventions for neurodegenerative diseases. This review emphasizes the need for further investigation into these compounds to realize their potential as neuroprotective agents fully.

Indexed as

AntioxidantsFuransNeurodegenerative DiseasesNeuroprotective AgentsAnimalsAnti-Inflammatory AgentsHumansMolecular StructureAnti-Inflammatory AgentsAntioxidantsFuransNeuroprotective Agentsanti-alzheimeranti-anxiolyticantidepressantanti-inflammatoryantioxidantanti-parkinsonian.Furan-containing compoundsneurodegenerative disorders

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.